Sonoma Pharmaceuticals (SNOA) Research & Development (2010 - 2026)

Sonoma Pharmaceuticals' Research & Development history runs 17 years deep, the most recent figure standing at $545000.0 for Q1 2026.

• On a quarterly basis, Research & Development rose 32.6% year-over-year to $545000.0 in Q1 2026; TTM through Mar 2026 was $2.3 million, a 25.19% increase from a year earlier, with the FY2026 full-year figure at $2.3 million, up 25.19% from the prior year.
• Research & Development eased to $545000.0 in Q1 2026 per SNOA's latest filing, from $557000.0 in the prior quarter.
• Across five years, Research & Development topped out at $601000.0 in Q4 2023 and bottomed at $4000.0 in Q1 2022.
• The 5-year median for Research & Development is $448500.0 (2024), against an average of $410437.5.
• Across the five-year window, Research & Development plunged 96.92% in 2022 and soared 4925.0% in 2023, its largest moves.
• Year by year, Research & Development stood at $200000.0 in 2022, then jumped by 200.5% to $601000.0 in 2023, then slipped by 28.95% to $427000.0 in 2024, then soared by 30.44% to $557000.0 in 2025, then fell by 2.15% to $545000.0 in 2026.
• Per Business Quant, the three latest SNOA Research & Development figures stand at $545000.0 (Q1 2026), $557000.0 (Q4 2025), and $575000.0 (Q3 2025).